@lag Thank you, but right or wrong, the first part of this statement, is inconsistent with my own current understanding. Again, perhaps my understanding of the term "metastatic" is wrong, but the glycoprotein PSMA, is said to be present on the surface of 'ALL' prostate cancer cells (not just the "metastatic" ones), right? I myself am classified as localized "non-metastatic", but my PSMA-PET scan results, show an abundance of radiotracer uptake, bound to the PSMA protein in "localized" (non-metastatic) cancer cells.

Otherwise, yes, Pluvicto apparently does indeed target that surface (PSMA) protein.